August 25, 2006
Genelabs Names Peter R. Young, Ph.D. as Vice President, Biology And Announces Resignation of Chief Financial Officer

August 9, 2006
Genelabs Announces Nasdaq Panel Decision to Grant Genelabs’ Request for Continued Listing on the Nasdaq Capital Market

August 3, 2006
GENELABS TECHNOLOGIES, INC. REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2006

June 30, 2006
Genelabs Technologies Raises $9 Million in Private Placement Financing

June 27, 2006
Genelabs Technologies Announces Agreement to Raise $9 Million in Private Placement Financing

June 12, 2006
Genelabs Announces Issuance of U.S. Patent on DHEA Composition and Method

June 9, 2006
Genelabs Announces Forecast of Mid-Year Cash Level and Notification from Nasdaq

June 5, 2006
GENELABS ANNOUNCES COLLABORATION FOR DEVELOPMENT AND COMMERCIALIZATION OF HCV NON-NUCLEOSIDE DRUG CANDIDATES

May 22, 2006
Genelabs Plans to Appeal Staff Determination Letter from Nasdaq Regarding its Listing on the Nasdaq Capital Market

May 15, 2006
GENELABS TECHNOLOGIES, INC. REPORTS FIRST QUARTER 2006 FINANCIAL RESULTS

April 24, 2006
Genelabs Technologies to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference

April 7, 2006
Genelabs Announces Receipt of Notice from Nasdaq and Drug Development Restructuring

April 3, 2006
GENELABS TECHNOLOGIES REPORTS 2005 YEAR-END AND FOURTH QUARTER FINANCIAL RESULTS

January 13, 2006
GENELABS UPDATES DEVELOPMENT OPTIONS FOR ITS INVESTIGATIONAL LUPUS DRUG AFTER FDA MEETING

January 9, 2006
Genelabs Regains Compliance with Nasdaq Capital Market Listing Requirements
 

© Genelabs Technologies, Inc. All rights reserved. - Terms of Use